PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Hartleben, G. ; Schorpp, K.K. ; Kwon, Y. ; Betz, B. ; Tsokanos, F.-F. ; Dantes, Z.* ; Schäfer, A.* ; Rothenaigner, I. ; Monroy Kuhn, J.M. ; Morigny, P. ; Mehr, L. ; Lin, S. ; Seitz, S. ; Tokarz, J. ; Artati, A. ; Adamski, J. ; Plettenburg, O. ; Lutter, D. ; Irmler, M. ; Beckers, J. ; Reichert, M.* ; Hadian, K. ; Zeigerer, A. ; Herzig, S. ; Berriel Diaz, M.

Combination therapies induce cancer cell death through the integrated stress response and disturbed pyrimidine metabolism.

EMBO Mol. Med.:e12461 (2021)
Publ. Version/Full Text DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
By accentuating drug efficacy and impeding resistance mechanisms, combinatorial, multi-agent therapies have emerged as key approaches in the treatment of complex diseases, most notably cancer. Using high-throughput drug screens, we uncovered distinct metabolic vulnerabilities and thereby identified drug combinations synergistically causing a starvation-like lethal catabolic response in tumor cells from different cancer entities. Domperidone, a dopamine receptor antagonist, as well as several tricyclic antidepressants (TCAs), including imipramine, induced cancer cell death in combination with the mitochondrial uncoupler niclosamide ethanolamine (NEN) through activation of the integrated stress response pathway and the catabolic CLEAR network. Using transcriptome and metabolome analyses, we characterized a combinatorial response, mainly driven by the transcription factors CHOP and TFE3, which resulted in cell death through enhanced pyrimidine catabolism as well as reduced pyrimidine synthesis. Remarkably, the drug combinations sensitized human organoid cultures to the standard-of-care chemotherapy paclitaxel. Thus, our combinatorial approach could be clinically implemented into established treatment regimen, which would be further facilitated by the advantages of drug repurposing.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
12.137
2.118
3
6
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Cancer Metabolism ; Integrated Stress Response ; Metabolic Vulnerabilities ; Pyrimidine Metabolism ; Tricyclic Antidepressants
Language english
Publication Year 2021
HGF-reported in Year 2021
ISSN (print) / ISBN 1757-4676
e-ISSN 1757-4684
Journal EMBO Molecular Medicine
Quellenangaben Volume: , Issue: , Pages: , Article Number: e12461 Supplement: ,
Publisher Wiley
Publishing Place Chichester
Reviewing status Peer reviewed
Institute(s) Institute of Diabetes and Cancer (IDC)
Institute of Molecular Toxicology and Pharmacology (TOX)
Institute of Diabetes and Obesity (IDO)
Molekulare Endokrinologie und Metabolismus (MEM)
Institute of Medicinal Chemistry (IMC)
Institute of Experimental Genetics (IEG)
CF Metabolomics & Proteomics (CF-MPC)
POF-Topic(s) 90000 - German Center for Diabetes Research
30203 - Molecular Targets and Therapies
30201 - Metabolic Health
30505 - New Technologies for Biomedical Discoveries
Research field(s) Helmholtz Diabetes Center
Enabling and Novel Technologies
Genetics and Epidemiology
PSP Element(s) G-501900-253
G-501900-251
G-505293-001
G-501900-254
G-502500-001
G-502297-001
G-505600-003
G-506300-001
G-502200-001
G-500600-004
A-630710-001
Grants Helmholtz Alliance "Aging and Metabolic Programming, AMPro"
German Research Foundation
DOI 10.15252/emmm.202012461
WOS ID WOS:000625463800001
Scopus ID 85101901759
PubMed ID 33665961
Erfassungsdatum 2021-03-15
[➜Report correction]